Algorithm

What Algorithm does

Algorithm SAL is a privately held Lebanese regional pharmaceutical company founded in 1961 (originally as Charles E. Frosst & Co. (M.E.) SAL, a subsidiary of Merck & Co. Inc.) and acquired by Droguerie De L'Union shareholders in December 1989. The company manufactures and commercializes pharmaceutical products across the MENA region, combining in-house differentiated generics (e.g., Ziorel, Ziorel Plus, Zevlen) with licensed products from international originators including Merck, Recordati, Organon, Teijin, Kowa, Advanz, Curax, and Biogen. Its therapeutic portfolio spans seven areas: antithrombotic therapy, central nervous system, diabetes, dyslipidemia, hypertension, obesity, and primary care, with more than 100 products in market.

The company operates two GMP-certified manufacturing facilities in Lebanon — a primary site in Zouk Mosbeh and an expanded, LEED Gold-certified plant in Zekrit — supported by Medical Affairs, Regulatory Affairs, Marketing, and Market Access functions. Algorithm distributes through a direct field sales force targeting physicians, pharmacists, and hospital procurement teams across 9+ MENA countries (Lebanon, Saudi Arabia, Kuwait, UAE, Jordan, Egypt, Iraq, and others), supplemented by channel partners such as Batterjee Pharma for Saudi localization and Bejaa Scientific Office for Iraq. In September 2025 it signed a landmark localization agreement with Batterjee Pharma, targeting full technology transfer by mid-2026 and becoming the first Lebanese company to lead portfolio localization in Saudi Arabia under Vision 2030.

Algorithm generates revenue through the manufacture, promotion, and distribution of branded pharmaceutical products via one-time license arrangements with multinational partners and direct sales of differentiated generics. Its go-to-market is enterprise field sales reinforced by medical congress participation, scientific symposia, continuing medical education, and site visits to its manufacturing facilities. The company is TRACE certified since 2019 and operates an FCPA-aligned compliance program, which underpins its standing as a trusted regional partner for multinational licensors.

Name

Algorithm

Legal name

Algorithm SAL

Website

https://algorithm-lb.com

Company type

Private

Founded year

1961

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Differentiated generics
• Cardiovascular medicines
• MENA pharmaceuticals
• Licensed pharma products

Headquarters

HQ city

Beirut

HQ country

Lebanon

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical product sales: Algorithm generates revenue through the manufacture, promotion, and distribution of branded pharmaceutical products. Revenue comes from licensed products sourced from international pharmaceutical partners and differentiated in-house generic products sold across MENA markets through direct sales channels and regional distributors.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Algorithm manufactures and commercializes branded pharmaceutical products under license from international companies (Merck, Recordati, Organon, Teijin, Kowa, Advanz, Curax) and differentiated in-house generics across seven therapeutic areas: Antithrombotic Therapy, Central Nervous System, Diabetes, Dyslipidemia, Hypertension, Obesity, and Primary Care. The company operates two GMP-certified manufacturing facilities in Lebanon and distributes its 100+ products through a regional field sales force and strategic distribution partnerships across 9+ MENA countries.

Product overview

Algorithm is a regional pharmaceutical company operating across the MENA region, committed to improving human health and well-being. The company manufactures and commercializes innovative pharmaceutical products both under license from international companies and as differentiated generics. Its therapeutic portfolio focuses on seven key therapeutic areas: Antithrombotic Therapy (including Aggrastat), Central Nervous System, Diabetes, Dyslipidemia (including Livazo), Hypertension (including Ziorel and Ziorel Plus), Obesity, and Primary Care (including cold/flu products, antibiotics like Zevlen, and gastro products like Exonar). The company operates two manufacturing facilities in Lebanon (Zouk and Zekrit) and distributes products across 9+ countries in the MENA region. Beyond its product portfolio, Algorithm provides access channels including Medical Affairs, Regulatory Affairs, Marketing, and Market Access services.

Differentiator

Problem solved

Functional benefit

Brands

• Livazo: Featured product for Dyslipidemia
• 123 Complete Cold, Cough and Flu
• Adenuric
• Aggrastat
• Exonar

Products and services

• Livazo
• Aggrastat
• Adenuric
• Zevlen
• Ziorel
• Ziorel Plus
• Exonar
• 123 Complete Cold, Cough and Flu
• 123 Cold & Flu

Quantifiable outcome

• Over 100 high-quality pharmaceutical products manufactured and distributed across MENA
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

13 partnerships are on record, tiered core and minor.

• Batterjee PharmacoreStrategic or Co-development Partner · 18 September 2025Algorithm and Batterjee Pharma signed a landmark strategic partnership agreement for local manufacturing of Algorithm's pharmaceutical products in the Kingdom of Saudi Arabia. The collaboration covers differentiated products targeting hyperlipidemia, dyslipidemia, hypertension, chronic weight management, and acute coronary syndrome, with full technology transfer expected by mid-2026. This aligns with Saudi Vision 2030's Health Sector Transformation Program.
• Bejaa Scientific OfficecoreChannel Partner/ Reseller/ Distributor · 24 May 2024Strategic partnership for registration, commercialization, and distribution of Algorithm's pharmaceutical products in Iraq. Unveiled at a high-profile event under the patronage of the Iraqi Minister of Health, represented by Pr. Salih Al-Hasnawi, with key stakeholders from the Iraqi healthcare ecosystem.
• Recordati IrelandcoreStrategic or Co-development Partner · 25 October 2022Recordati Ireland visits to Algorithm's Zekrit manufacturing facility. The partnership dates back to 1997; Algorithm is responsible for manufacturing, promotion, and distribution of Recordati products within cardiac and primary care therapeutic areas in the Levant and Gulf region.
• Lebanese American University (LAU) School of PharmacyminorStrategic or Co-development Partner · 31 May 2019Algorithm partners with LAU School of Pharmacy for the 5th consecutive year providing one-month industrial rotation for Doctor of Pharmacy (Pharm.D.) students. Algorithm engages its technical and commercial departments to provide practical insights including field experience.
• BiogencoreStrategic or Co-development Partner · 16 November 201720 years of partnership between Biologix and Biogen. Senior leadership from Biogen visited Algorithm facilities to celebrate the milestone, reflecting on successes and challenges and emphasizing commitment to serving patients in the Middle East.
• RecordaticoreStrategic or Co-development PartnerLong-term strategic licensing and co-development partnership for cardiac and primary care products. Algorithm manufactures, promotes, and distributes Recordati products across the Levant and Gulf region.
• MerckcoreStrategic or Co-development PartnerHistorical licensing partnership. Algorithm originated as Charles E. Frosst & Co. (M.E.) SAL, a subsidiary of Merck & Co. Inc. (MSD), before acquisition in December 1989.
• OrganoncoreStrategic or Co-development PartnerStrategic partnership for pharmaceutical products promoted and distributed by Algorithm in MENA markets under license from Organon.
• TeijincoreStrategic or Co-development PartnerLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Teijin.
• KowacoreStrategic or Co-development PartnerLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Kowa.
• AdvanzcoreStrategic or Co-development PartnerLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Advanz.
• CuraxcoreStrategic or Co-development PartnerLicensing partnership for pharmaceutical products distributed by Algorithm across MENA markets under license from Curax.
• Biologix FZCocoreStrategic or Co-development PartnerBiologix specializes in bringing innovative drugs from multinational manufacturers to the MENA market through its network of over 17 strategic locations. Biologix is part of the Algorithm group operating alongside Algorithm Pharmaceutical Manufacturers, covering both licensed products and differentiated generics.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/algorithmsal

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Algorithm